Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Products under Development by Stage of Development | 9 | 1 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Products under Development by Therapy Area | 10 | 1 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Products under Development by Indication | 11 | 2 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Products under Development by Companies | 15 | 6 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Products under Development by Universities/Institutes | 21 | 2 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Therapeutics Assessment | 23 | 6 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Companies Involved in Therapeutics Development | 29 | 15 |
| 4SC AG | 29 | 1 |
| Acetylon Pharmaceuticals, Inc. | 30 | 1 |
| Chipscreen Biosciences Ltd | 31 | 1 |
| Curis, Inc. | 32 | 1 |
| GlaxoSmithKline Plc | 33 | 1 |
| HitGen LTD | 34 | 1 |
| IRBM Science Park SpA | 35 | 1 |
| Italfarmaco S.p.A. | 36 | 1 |
| MEI Pharma, Inc. | 37 | 1 |
| Merck &Co., Inc. | 38 | 1 |
| Mirati Therapeutics Inc. | 39 | 1 |
| Oncolys BioPharma Inc | 40 | 1 |
| Sigma-Tau S.p.A. | 41 | 1 |
| Syndax Pharmaceuticals Inc | 42 | 1 |
| TetraLogic Pharmaceuticals | 43 | 1 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drug Profiles | 44 | 51 |
| 4SC-202 Drug Profile | 44 | 3 |
| ACY-738 Drug Profile | 47 | 1 |
| ACY-957 Drug Profile | 48 | 2 |
| crocetin Drug Profile | 50 | 1 |
| CS-3158 Drug Profile | 51 | 1 |
| CUDC-907 Drug Profile | 52 | 5 |
| entinostat Drug Profile | 57 | 7 |
| givinostat Drug Profile | 64 | 2 |
| HG-3001 Drug Profile | 66 | 1 |
| Largazole Drug Profile | 67 | 1 |
| mocetinostat Drug Profile | 68 | 5 |
| OBP-801 Drug Profile | 73 | 1 |
| pracinostat Drug Profile | 74 | 6 |
| remetinostat Drug Profile | 80 | 2 |
| Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma Drug Profile | 82 | 1 |
| Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia Drug Profile | 83 | 1 |
| Small Molecule to Inhibit Histone Deacetylases for Oncology Drug Profile | 84 | 1 |
| Small Molecules to Inhibit BRD4 and HDAC1 for Oncology Drug Profile | 85 | 1 |
| Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology Drug Profile | 86 | 1 |
| ST-3595 Drug Profile | 87 | 1 |
| tucidinostat Drug Profile | 88 | 3 |
| vorinostat Drug Profile | 91 | 4 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Dormant Projects | 95 | 4 |
| Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Featured News &Press Releases | 99 | 10 |
| Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy | 99 | 1 |
| Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association | 99 | 1 |
| Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program | 100 | 1 |
| Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting | 100 | 1 |
| May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting | 100 | 1 |
| May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One | 101 | 1 |
| Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting | 102 | 2 |
| Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting | 104 | 1 |
| Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology | 104 | 1 |
| Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting | 104 | 1 |
| Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer | 105 | 1 |
| Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team | 105 | 1 |
| Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan | 106 | 1 |
| Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study | 106 | 1 |
| Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models | 107 | 2 |
| Appendix | 109 | 2 |
| Methodology | 109 | 1 |
| Coverage | 109 | 1 |
| Secondary Research | 109 | 1 |
| Primary Research | 109 | 1 |
| Expert Panel Validation | 109 | 1 |
| Contact Us | 109 | 1 |
| Disclaimer | 110 | 1 |
